AVEO Pharma

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AVEO is a late-stage biopharmaceutical company focused on the discovery and development of targeted cancer therapeutics. AVEO's proprietary, integrated cancer biology platform enables the company to pursue highly efficient drug development strategies in oncology that increase the probability of clinical success and provides a discovery engine for high-value targets and therapies. This approach has resulted in a balanced pipeline of novel cancer therapies focused on well-validated targets (VEGFR, EGFR) and promising novel targets (HGF, FGFR, ErbB3 and NOTCH), as well as collaborations with Eli Lilly, Merck, OSI Pharmaceuticals, Schering-Plough, and Biogen Idec. The company was established in 2001 and is based in Cambridge, Massachusetts.

– Industry veteran brings extensive clinical development experience to AVEO Oncology leadership team as Chief Medical Officer –

CORRECTION – AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee

AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee

BOSTON, Feb. 06, 2024 (GLOBE NEWSWIRE) -- AVEO Oncology , an LG Chem company (“AVEO”), today announced The Oncologist has published a post-hoc analysis of long-term progression free survival, overall survival and safety data from the Phase 3 TIVO-3 trial evaluating FOTIVDA® (tivozanib) in patients with relapsed or refractory (R/R) advanced renal cell carcinoma (RCC). In the publication, FOTIVDA demonstrated a consistent safety profile and a long-term survival benefit in patients who were alive and progression-free at 12 months, suggesting a durable clinical benefit and safety across age groups regardless of prior treatment.

AVEO Oncology Announces Publication of Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial in The Oncologist

BOSTON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”), an LG Chem company, today announced enrollment of the first patient in the FIERCE-HN trial, a global, multicenter, randomized, double-blind, placebo-controlled, phase 3 clinical trial evaluating ficlatuzumab in combination with ERBITUX® (cetuximab), an anti-EGFR antibody, in patients with human papillomavirus (HPV)-negative recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Ficlatuzumab is AVEO's investigational antibody that targets hepatocyte growth factor (HGF).

AVEO Oncology Enrolls First Patient in Pivotal FIERCE-HN Clinical Trial to Evaluate Ficlatuzumab in Combination with ERBITUX® (cetuximab) in Patients with HPV-negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

AVEO to Become the U.S. Foundation for LG Chem Life Sciences' Oncology Division AVEO to Become the U.S. Foundation for LG Chem Life Sciences' Oncology Division

LG Chem Completes Acquisition of AVEO Oncology

BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”) (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, announced that at a special meeting of stockholders (the “Special Meeting”) held today, AVEO stockholders approved the adoption of the Agreement and Plan of Merger among LG Chem, Ltd. (“LG Chem”), a subsidiary of LG Chem and AVEO (the “merger agreement”). As previously announced, under the terms of the merger agreement, AVEO stockholders will receive $15.00 per share in cash upon the closing of the transaction.

AVEO Oncology Stockholders Approve Acquisition by LG Chem

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend that AVEO Stockholders Vote “FOR” the Transaction Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend that AVEO Stockholders Vote “FOR” the Transaction

AVEO Oncology Reminds Stockholders to Vote “FOR” All-Cash Transaction with LG Chem in advance of the Special Meeting of Stockholders

Cabaletta Bio

Verona Pharma

Wave Life Sciences

We present four biotech stocks, AVEO, CABA, VRNA and WVE, which despite the current volatile market, have provided more than twice the returns in 2022.

4 Drug Stocks That More Than Doubled This Year

Here is how AVEO Pharmaceuticals (AVEO) and Merit Medical (MMSI) have performed compared to their sector so far this year.

Are Medical Stocks Lagging AVEO Pharmaceuticals (AVEO) This Year?

AVEO Oncology (AVEO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

AVEO Oncology (AVEO): Strong Industry, Solid Earnings Estimate Revisions

Does AVEO Pharmaceuticals (AVEO) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes AVEO Pharmaceuticals (AVEO) a Strong Momentum Stock: Buy Now?

AVEO (AVEO) delivered earnings and revenue surprises of 43.75% and 1.67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

AVEO Pharmaceuticals (AVEO) Reports Q3 Loss, Tops Revenue Estimates

– Total Q3 2022 Net Revenue of $30.4 million, including $30.2 million of FOTIVDA® (tivozanib) U.S. Net Product Revenue –

AVEO Oncology Reports Third Quarter 2022 Financial Results

AVEO (AVEO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AVEO Pharmaceuticals (AVEO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

AVEO Oncology's (AVEO) third-quarter earnings is expected to reflect strong Fotivda sales. The company is likely to beat the Zacks Consensus Estimate.

AVEO Oncology (AVEO) to Report Q3 Earnings: Is a Beat in Store?

NEW YORK , Oct. 24, 2022 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating AVEO Pharmaceuticals, Inc. (AVEO), relating to its proposed acquisition by LG Chem, Ltd. Under the terms of the agreement, AVEO shareholders are expected to receive $15.00 in cash per share they own.

STOCKHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of AVEO Pharmaceuticals, Inc. - AVEO

NEW YORK , Oct. 21, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of AVEO Pharmaceuticals, Inc. ("AVEO" or the "Company") (NASDAQ: AVEO), in connection with the proposed acquisition of the Company by LG Chem, Ltd. Under the terms of the merger agreement, the Company's shareholders will receive $15.00 in cash for each share of AVEO common stock owned.

SHAREHOLDER ALERT: Weiss Law Investigates AVEO Pharmaceuticals, Inc.

Aveo Pharmaceuticals (AVEO) is set to be acquired by LG Chem for an aggregate amount of $566 billion. The deal is expected to close by early 2023.

AVEO Pharmaceuticals (AVEO) Inks Deal to be Acquired by LG Chem

LG Chem is buying AVEO Oncology for $566 million. These are the details.

Why LG Chem Is Buying AVEO Oncology (AVEO) For $566 Million

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C.

AVEO ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AVEO Oncology - AVEO

Wilmington, Delaware--(Newsfile Corp. - October 18, 2022) - Rigrodsky Law, P.A. is investigating AVEO Pharmaceuticals, Inc. ("AVEO") (NASDAQ CM: AVEO) regarding possible breaches of fiduciary duties and other violations of law related to AVEO's agreement to be acquired by LG Chem, Ltd. Under the terms of the agreement, AVEO's shareholders will receive $15.00 per share.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-aveo-pharmaceuticals-inc. To contact Seth D. Rigrodsky or Gina M.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating AVEO Pharmaceuticals, Inc. Buyout

Aveo Pharmaceuticals Inc (NASDAQ:AVEO) stock is soaring today, up 40.7% at $14.74 at last glance, after news that South Korean chemical company LG Chem plans to buy the biopharmaceutical name for $15 per share, or roughly $566 million, in an all-cash deal.

Biopharma Stock Soaring on Buyout News

MILWAUKEE , Oct. 18, 2022 /PRNewswire/ -- Ademi LLP is investigating AVEO (NASDAQ: AVEO) for possible breaches of fiduciary duty and other violations of law in its transaction with LG Chem.  Click here to learn how to join the action https://www.ademilaw.com/case/aveo-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether AVEO Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with LG Chem

Aveo Oncology agreed to be acquired by Korea's LG Chem on Tuesday, and Aveo stock skyrocketed to a near two-year high on the news. The post Aveo Stock Continues Its Bullish Run After Snagging $566 Million LG Chem Buyout appeared first on Investor's Business Daily.

Aveo Stock Continues Its Bullish Run After Snagging $566 Million LG Chem Buyout

AVEO Oncology (NASDAQ: AVEO ) stock jumped 40% in premarket trading after LG Chem (OTCMKTS:LGCLF) said it would buy the company for $15/share in cash. The price implies a value of $566 million for AVEO.

News for AVEO Pharma Stock (AVEO)